Januvia costs around $527 per month at list price because it has been protected by patents that block generic competition, it faces no meaningful price pressure from rival drugs in its class, and the pharmacy supply chain adds layers of cost between the manufacturer and the patient. That’s roughly $6,300 a year for a single diabetes medication, and until very recently, there was no mechanism to force the price lower.
The good news: several forces are converging to bring the price down sharply starting in 2026. Here’s what’s driving the current cost and what’s changing.
Patent Protection Kept Generics Off the Market
The single biggest reason Januvia costs what it does is that Merck held exclusive rights to sell it for nearly two decades. The FDA approved Januvia in 2006, and Merck successfully defended its patents in court, with a federal appeals court ruling that patent protection extends through May 2027 (including six months of pediatric exclusivity). Without generic alternatives, Merck could set and raise the price with no competition to undercut it.
Merck also settled with multiple generic manufacturers, agreeing to let them bring their versions to market in May 2026 or earlier under certain conditions. That settlement date, not the patent expiration itself, is what actually determines when cheaper alternatives will appear. The FDA has already approved the first generic version of sitagliptin (the active ingredient in Januvia), with Watson Laboratories receiving approval in December 2025. A generic combination of sitagliptin and metformin was also approved around the same time. Approval doesn’t guarantee immediate availability on pharmacy shelves, but it means the legal and regulatory barriers are essentially cleared.
Other Drugs in the Same Class Cost Nearly as Much
Januvia belongs to a group of diabetes medications called DPP-4 inhibitors, which work by helping your body produce more insulin after meals. The problem is that every drug in this class carries a similar price tag. Tradjenta runs about $931 per year, Onglyza about $1,036, and Januvia about $1,078. When your competitors charge the same amount, there’s no incentive to lower your price. Insurers and pharmacy benefit managers can’t credibly threaten to drop Januvia from their coverage lists if switching patients to a rival saves almost nothing.
The Gap Between List Price and What People Pay
Januvia’s list price in 2023 was $527 for a 30-day supply, but the average transaction price across U.S. pharmacies was $488. That $39 difference reflects point-of-sale rebate discounts, but it doesn’t capture the larger rebates that flow between Merck and pharmacy benefit managers behind the scenes. These rebates are negotiated confidentially, and they give middlemen in the supply chain a financial reason to keep high list prices intact: bigger list prices mean bigger rebate dollars. The system rewards inflated sticker prices even when patients with high-deductible plans or no insurance end up paying closer to that full amount.
If you have insurance with a copay structure, you may pay far less than $527. But if you’re in the deductible phase of a high-deductible plan, or if you’re uninsured, you’re exposed to something much closer to the list price.
Medicare Negotiation Is Cutting the Price by 79%
Januvia was one of the first drugs selected for price negotiation under the Inflation Reduction Act. The Centers for Medicare and Medicaid Services negotiated a maximum fair price of $113 for a 30-day supply, a 79% discount from the 2023 list price. That negotiated price takes effect January 1, 2026, and applies to Medicare Part D enrollees.
This is the steepest discount CMS secured in its initial round of negotiations, which covered drugs ranging from blood thinners to cancer treatments. For Medicare patients specifically, this will transform Januvia from one of the most expensive diabetes pills to something much more manageable. The negotiated price won’t directly apply to people with private insurance, but the arrival of generics around the same time should push prices down across the board.
What Changes in 2026
Two things happen almost simultaneously. The Medicare negotiated price kicks in on January 1, 2026, and generic manufacturers have settlement agreements allowing them to launch as early as May 2026. Generic diabetes drugs typically cost a fraction of the brand-name version, often 80% to 90% less once multiple manufacturers are competing. Within a year or two of generic entry, you can reasonably expect the price of sitagliptin to drop well below $100 per month at most pharmacies.
If you’re currently paying full price or a high copay, the landscape is about to shift significantly. In the meantime, your options for reducing cost depend on your insurance situation.
How to Lower Your Cost Right Now
Merck runs a patient assistance program that provides Januvia free of charge to eligible individuals. You qualify if your household income is $63,840 or less for an individual, $86,560 or less for a couple, or $132,000 or less for a family of four. You don’t need to be a U.S. citizen, just a resident, including those in U.S. territories. The program is primarily designed for uninsured patients, but people with insurance can request an exception if they can demonstrate financial and medical hardship.
If you don’t qualify for the assistance program, ask your doctor whether a different medication class makes sense. GLP-1 receptor agonists and SGLT2 inhibitors are two newer drug classes for type 2 diabetes that work through different mechanisms, and some have generic versions or lower copays depending on your plan. Your pharmacist can also run your prescription through a discount card to check whether it beats your insurance price, which sometimes happens with high-deductible plans.